Breaking AI & Tech News Analyzed

The world’s largest randomised trial of a multi‑cancer early detection (MCED) blood test, involving 142,942 NHS participants, did not achieve its main aim of cutting late‑stage cancer diagnoses, according to data presented at the ASCO annual meeting in Chicago.Trial Overview and Primary ObjectiveThe study enrolled adults aged 50‑77 with no cancer symptoms, assigning half to annual Galleri testing alongside standard screening and the other half to standard screening alone. Positive Galleri results triggered diagnostic follow‑up, mirroring the protocol for symptomatic participants in both arms.Key Findings and Statistical OutcomesParticipants: 142,942 screened over three years.Primary endpoint: Combined stage III and IV diagnoses across 12 pre‑specified cancers.Result: No statistically significant reduction in advanced‑stage cancers in the Galleri arm versus control.Secondary signal: Stage IV cancers fell by 14% in the Galleri group, a finding the company Grail highlighted as encouraging.Dr Julie Gralow, ASCO’s chief medical officer, noted the trial showed “some encouraging trends toward tumour downstaging” but emphasized the primary endpoint was not met.Implications for NHS Cancer Screening StrategyExperts such as Prof Richard Houlston (Institute of Cancer Research) warned that the lack of a primary‑endpoint hit undermines any justification for nationwide adoption of Galleri. Prof Peter Johnson, NHS England’s national clinical director for cancer, said the NHS will scrutinise the full data before deciding on future implementation.The trial’s outcome raises questions about the cost‑effectiveness of MCED tests at population scale and may temper enthusiasm for rapid integration into existing screening programmes.Future Directions and Remaining QuestionsMortality outcomes, expected in the next few years, will be critical to assess whether earlier detection translates into survival benefits. Researchers and policymakers will likely await these results before committing to broader rollout, while Grail may refine its assay based on the secondary findings.

FCA has begun a 12‑week trial with US data‑analytics firm Palantir to test AI‑driven crime detection, while MPs and privacy groups warn the partnership could give the Trump administration a backdoor to UK financial data under the US Cloud Act.Details of the FCA‑Palantir AI trialThe trial will see Palantir’s platforms applied to a wide range of FCA data sets, including case intelligence files, lender fraud reports, consumer complaints and social‑media monitoring. The arrangement is at the 12‑week pilot stage and is intended to improve the regulator’s ability to spot financial crime.Financial stakes and contractual backdrop$375bn valuation of Palantir, co‑founded by Trump‑supporting billionaire Peter Thiel.Palantir holds contracts worth over £500m with NHS England and the Ministry of Defence.London mayor Sadiq Khan blocked a separate £50m two‑year deal between Palantir and the Metropolitan Police.Legal and sovereignty implicationsCritics argue that under the US Cloud Act, US authorities could compel Palantir to hand over any data it processes, potentially exposing UK citizens’ financial information to US surveillance regimes such as the Patriot Act and FISA. The FCA maintains that Palantir is only a “data processor”, that all data remains encrypted, and that the regulator retains control.Potential impact on UK data policyIf the trial proceeds without robust safeguards, it could set a precedent for further reliance on US‑based AI vendors, eroding confidence in the UK’s data sovereignty and prompting stricter procurement rules. Conversely, a successful pilot could accelerate AI adoption across UK regulators, influencing future contracts with private tech firms.Outlook and next stepsParliamentary committees are expected to request a detailed legal review of the Cloud Act’s applicability. The FCA has pledged to publish trial results, but pressure from MPs like Martin Wrigley suggests additional oversight may be imposed before any wider rollout.

Palantir Accuses Mayor of Prioritising Politics Over SafetyPalantir says London mayor Sadiq Khan is “politicising procurement” by blocking a two‑year, £50 million AI contract for the Metropolitan Police, arguing the move jeopardises public safety.Mayor Blocks £50m AI Procurement Deal with Met PoliceKhan’s office cited a “clear and serious breach” of procurement rules and rejected the plan for the Met to use Palantir’s AI to process intelligence in criminal investigations. The decision was first reported by the Guardian on 21 May 2026.Financial Stakes: £50m Contract and Wider Government Deals£50 million – value of the blocked Met Police contract.£330 million – NHS England deal with Palantir.£240 million – Ministry of Defence agreement.Less than £500,000 – earlier separate AI pilot with the Met to detect rogue officers.Political Fallout and Policing Implications in LondonThe move has split Labour MPs: Rosena Allin‑Khan and Clive Lewis praised the block, while Stella Creasy condemned Palantir’s CEO for “using sexual‑abuse allegations to attack the mayor”. The Metropolitan Police Federation called the AI system “big brother”. Business Secretary Peter Kyle defended Palantir’s capabilities and urged Khan to explain his decision.Future of AI Procurement and Domestic Tech AlternativesKhan’s stance may encourage a shift toward British‑owned AI solutions, echoing Kyle’s call for more investment in domestic firms. Ongoing debates about foreign AI providers could reshape how UK public services adopt advanced technology, with potential impacts on policing effectiveness and public trust.

The latest analysis by Cancer Research UK reveals that melanoma, the most serious form of skin cancer, hit a historic high in the United Kingdom last year, with 20,980 diagnoses in 2022. Experts warn that without stronger prevention measures, annual cases could climb to 26,500 by 2040, coinciding with hotter summers and an ageing demographic. Record Melanoma Diagnoses in 2022 For the first time, UK melanoma cases have exceeded the 20,000 mark. The surge reflects broader trends in skin‑cancer incidence and underscores the urgency of public‑health interventions. Projected Growth to 26,500 Cases by 2040 Forecasted annual cases for 2040: 26,500 Increase of 23% among men Increase of 26% among women Drivers: ageing population, higher UV exposure, and lifestyle factors Public Health Implications Amid Heatwave Alerts Heat health alerts have been issued for the upcoming bank‑holiday weekend, with temperatures expected to reach up to 30°C in parts of England. Elevated UV levels amplify the risk of sunburn and, consequently, melanoma development, especially for vulnerable groups. Preventive Strategies and Policy Recommendations Key voices—including Michelle Mitchell, CEO of Cancer Research UK, and Prof Peter Johnson, NHS England’s national clinical director for cancer—stress the importance of: Seeking shade during peak sun hours Wearing protective clothing, hats, and sunglasses Applying broad‑spectrum sunscreen with at least SPF 30 and reapplying regularly Promptly consulting a GP about new or changing moles, sores, or skin patches Outlook for Sun Safety and Cancer Prevention If the public adopts these preventive measures, the rise in melanoma cases could be mitigated despite demographic pressures and hotter summers. Ongoing education, stronger sunscreen regulations, and targeted campaigns during heatwaves are likely to shape the trajectory of skin‑cancer incidence in the UK over the next two decades.

Lead: Trust Cracks Over a £330‑Million NHS DealCritics say Palantir's defence‑linked ethos clashes with the health sector, prompting the UK government to reconsider a six‑year, £400 million contract that gives the firm extensive access to patient data.Erosion of Trust in Palantir’s NHS ContractThe partnership began in March 2020 with a symbolic £1‑pound NHS contract that expanded into a £330‑million Federated Data Platform (FDP) programme. Recent revelations – including a 22‑point manifesto calling for universal military service and AI weapons – have intensified scrutiny from the Good Law Project and other watchdogs.Palantir’s X post sparked renewed debate about its suitability as a health‑data steward.Legal pressure forced NHS England to release a partially redacted version of the FDP contract.Officials are openly discussing a 2027 break point for the agreement.Financial Stakes and Contract ScaleThe original £1‑pound contract grew into a six‑year relationship valued at nearly £400 million ($546 m). The flagship FDP programme alone is priced at £330‑million ($450 m) and underpins data analytics across at least ten UK government departments.Contract duration: 2020‑2026, with potential extension discussions for 2027.Key figures: £330‑million FDP, £400‑million total NHS spend.Governance Concerns and Political BacklashCritics argue that the shared architecture between Palantir’s defence‑focused Gotham platform and the civilian‑oriented Foundry system creates a “governance problem” that has not been fully addressed. Duncan McCann of the Good Law Project warns that a defence contractor’s values differ fundamentally from those of a public health service.Academic Eerke Boiten highlights the difficulty of verifying compliance, noting that similar trust gaps exist with other US tech firms operating in the NHS.Key concerns include:Unlimited employee access to patient data, as reported by the Financial Times.Opaque pseudonymisation methods – roughly 100 pages of the contract remain withheld.Potential data aggregation across multiple government departments, despite Palantir’s claim that each engagement is “walled off”.Future Outlook for Palantir’s NHS PartnershipAnalysts suggest that the NHS may either renegotiate the FDP terms, seek alternative analytics platforms, or terminate the contract by 2027 if public confidence does not improve. Transparency measures such as publishing the full Data Protection Impact Assessment (DPIA) could mitigate some concerns, but the underlying tension between defence‑origin values and public‑health responsibilities is likely to persist.

The Lead: A Breach of Trust in Public Health DataMPs have issued a stark warning regarding the NHS's decision to grant Palantir access to identifiable patient data, deeming the move 'dangerous' and likely to erode public confidence in data privacy standards. The controversy centers on the company's ability to view raw, non-anonymized health records before they are processed, a practice that contradicts standard security protocols.The Controversy: Access Before PseudonymizationThe core technical issue lies in the mechanism of access. Unlike standard protocols, NHS England has permitted contractors to view raw, identifiable patient records before they are anonymized. This bypasses a critical security layer, raising alarms about the potential for misuse or accidental exposure. The Federated Data Platform (FDP) was designed to integrate scattered datasets, but allowing 'unlimited access' to non-NHSE staff has triggered a significant security review.The Financial and Political StakesThe deal is valued at £330m, but the political cost is mounting. Rachael Maskell and Martin Wrigley have publicly condemned the project, while polling indicates that 40% of the UK public distrusts Palantir with sensitive health information, and two-thirds are generally concerned about the company's expanding public sector role. The company's history—supporting ICE immigration enforcement and military operations—clashes with the public's expectation of a healthcare provider.The Expanding Role of Private Tech in Public HealthThis incident is part of a broader pattern. Palantir is simultaneously negotiating with the Metropolitan Police for AI intelligence analysis. The 'cavalier attitude' cited by MPs suggests a systemic failure in 'security by design.' The Patients Association and campaign groups like Foxglove argue that patients never consented to having their data accessed by a company with a record in targeting people, not caring for them.Future Outlook: Heightened Scrutiny and Regulatory RiskGiven the intense scrutiny from both backbench MPs and the public, the project faces an uncertain future. The government will likely face increasing pressure to either halt the access to identifiable data or implement significantly stricter, auditable safeguards to restore trust. The risk of a public backlash could force a re-evaluation of how private contractors are integrated into critical national infrastructure.

For the first time, thousands of cancer patients from Black and minority ethnic backgrounds will benefit from an enhanced genetic test offered by the NHS. The new screening expands the panel of DPYD gene variants from four to five, directly addressing a long‑standing bias that left non‑white patients vulnerable to dangerous chemotherapy side‑effects. In England, patients slated for chemotherapy undergo a genetic check that can guide dose adjustments and mitigate adverse reactions such as mouth sores, hair loss, nausea, fatigue, and, in severe cases, death. Up to 40% of the 38,000 individuals receiving fluoropyrimidine‑based chemotherapy each year experience a harmful drug reaction. Previously, the test only targeted four DPYD variants common in people of European descent, meaning many Black patients received inaccurate “all‑clear” results. The addition of a fifth variant—more prevalent among African, Caribbean and other minority groups—means clinicians can now identify patients at risk who were previously missed. Since its rollout at Manchester University NHS Foundation Trust last September, three minority‑ethnic patients have had their initial chemotherapy doses adjusted, lowering their chance of a potentially fatal reaction. Dr Veline L’Esperance, senior clinical adviser at the NHS Race and Health Observatory, called the change “tangible results for patients who have historically been left behind.” She emphasized that the update shifts the discussion on ethnic health inequality from rhetoric to actionable care. Prof Habib Naqvi, chief executive of the NHS Race and Health Observatory, described the development as a “groundbreaking outcome” for chemotherapy safety, while noting that ethnic minorities remain under‑represented in genomic research and biobanks. He warned that broader inclusion is essential for the promised benefits of precision medicine to reach all communities. Prof Dame Sue Hill, chief scientific officer for NHS England, highlighted the significance of discovering the fifth variant: “Personalising chemotherapy based on genetics can save lives and reduce harmful side‑effects, especially for patients of African ancestry.” She added that the North West NHS Genomic Medicine Service has already demonstrated the practical impact of this approach. These steps come amid broader evidence that minority patients in the UK face longer diagnostic waits, more GP visits before a cancer diagnosis, and lower perceived support during treatment. The expanded DPYD test represents a concrete effort to close those gaps and ensure equitable, science‑driven care for all cancer patients.

Palantir’s claim that opposition to its NHS contract is driven by ideology was rebuked by Chi Onwurah, the Labour MP who chairs Parliament’s science, innovation and technology select committee. Onwurah said it is appropriate for ministers to explore a break‑clause option in the deal, underscoring the seriousness of the concerns raised. Louis Mosley, Palantir’s UK executive vice‑chair, had urged the government not to succumb to “ideologically motivated campaigners” as officials weighed a way out of a £330 million contract to deliver the Federated Data Platform (FDP) for NHS England. Ministers have now asked for advice on triggering the contract’s break clause amid growing scrutiny of Palantir’s expanding role in the public sector. The FDP is an AI‑enabled platform designed to integrate disparate health information across the NHS. Palantir already holds contracts with the Ministry of Defence, several police forces and the UK’s financial watchdog, the FCA. Onwurah’s cross‑party committee is set to publish its report in the coming weeks, covering the digital reorganisation of government services and the role of AI after a series of hearings that included experts, NHS leaders and representatives from companies such as Palantir. She identified three core issues: the manner in which the contract was awarded, the handling of patient data and the resulting trust deficit within the NHS, and the involvement of Peter Mandelson through his firm Global Counsel. “These are not fringe ideological concerns,” Onwurah told the Guardian. “They relate to contract transparency, vendor lock‑in, value for money and data security – matters that should concern everyone pushing the NHS towards digital transformation.” She added that the NHS’s post‑COVID fatigue and austerity‑driven burnout make any additional trust‑related resentment a significant barrier to progress. Onwurah noted that Palantir secured the contract after providing services to the NHS at a nominal cost – a tactic often used by large tech firms to position themselves as the most attractive government supplier. “It is right for the government to explore all options, including breaking the contract, given ongoing concerns about FDP uptake while Palantir remains at the helm,” she said. Liberal Democrat MP Martin Wrigley, also on the committee, urged the government to commission a new consortium of UK‑based tech experts to build a home‑grown NHS platform. During a previous committee appearance, Mosley accused British doctors of placing “ideology over patient interest” after they challenged the data‑processing contract. Speaking to the Times, Mosley warned that removing Palantir could jeopardise patient care and stall solutions to the NHS’s biggest challenges, arguing that the campaign against the firm would do more harm than good.

The UK's National Health Service (NHS) is facing potential medicine shortages due to supply chain disruptions, with the head of NHS England, Jim Mackey, warning that some medicines could run out in weeks or even days. Mackey cited the country's reliance on imports, with 75% of medicines coming from abroad, as a major concern.Mackey revealed that a team is in place to focus on identifying potential risks in the supply chain, and that the NHS is working to mitigate the impact of any disruptions. He stated that the NHS generally has enough medicine to last a few weeks, but that some products may only have days' worth of supply.The concerns about medicine shortages come amid the ongoing conflict in the Middle East, which has raised worries about cost implications and supply disruption. Experts have noted that pharmacies are seeing disturbing spikes in prices, which can be an early indicator of challenges.The UK government has stated that there are currently no reported medicine shortages as a result of the conflict, but that they are monitoring the situation closely and have established processes in place to manage disruption across the health and social care sector.